Strong Revenue Growth:
Reported three-year revenue growth of 1,061% and placement on the 2026 Inc. 5000 underscore rapid top-line expansion. While absolute revenue is not disclosed, the growth trajectory across 2022–2025 is clearly strong.
Investor Backing & Capital Strength:
An $80 million Series C in April 2026, bringing total funding above $160 million and a reported $955 million valuation, signals substantial capital support. Participation from established investors and continued financing provide resources for expansion.
Market Expansion:
Customer count reportedly grew from more than 200 in 2024 to over 500 by 2026, including 16 of the top 20 MedTech companies. This indicates broadening adoption across both emerging firms and large enterprises.
